India’s Foreign Investment Promotion Board deferred a ruling on a $1.6 billion planned buyout of Agila Specialties by US firm Mylan Inc., putting at least a temporary stop to a deal part of a larger trend of foreign ownership of India-based cancer drug companies. Reports say the Department of Industrial Policy and Promotion recently raised concerns that foreign takeovers of pharmaceutical companies is threatening the cancer drug and vaccine market. Government officials cited a 2009 deal that saw a French takeover of Hepatitis B vaccine maker Sanofi Aventis; the result of the deal was skyrocketed vaccine prices in the country. DIPP’s foreign investment board is looking to prevent another such situation through halting the recent buyout, which would be one of the largest in the pharmaceutical sector in recent years, say reports.
Full Content: Economic Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI